The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Exenatide (Byetta) is a GLP-1-receptor agonist that recently was FDA-approved for treating type 2 diabetes. In an industry-sponsored randomized trial, 336 patients with suboptimally controlled ...

The biggest stories of the day delivered to your inbox.

A long-standing practice of Autocar India’s long-term fleet has been turned on its head by the MG Comet. For years, we’d run our respective long-termers (usually small cars) on the daily ...

Only two trials in the meta-analysis reported on BMD change. One trial found once-weekly exenatide 2 mg was associated with a greater increase in lumbar spine BMD at 3 months compared with placebo.

The new-generation MG ZS arrived here late last year with hybrid power, and now more affordable, exclusively petrol-powered models are coming. They’ll arrive in local showrooms from mid-February, with ...